Skip to main content
SpringerLink
Log in

Medullary Cancer

  • Chapter
Management of Thyroid Cancer and Related Nodular Disease

  • 820 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gilliland FD, et al. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer. 1997;79(3):564–73.

    PubMed  CAS  Google Scholar 

  2. Marsh DJ, Learoyd DL, Robinson BG. Medullary thyroid carcinoma: recent advances and management update. Thyroid. 1995;5(5):407–24.

    PubMed  CAS  Google Scholar 

  3. Bhattacharyya N. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngol Clin North Am. 2003; 128:115–25.

    Google Scholar 

  4. Palestini N, Tagliabue M, Cestino L, Farnetti A, Rossetto R, Vendrame A. [Treatment of familial medullary thyroid carcinoma]. Minerva Chir. 2003; 58(6):801–9.

    PubMed  CAS  Google Scholar 

  5. Raue F, Kotzerke J, Reinwein D, et al. Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Investig. 1993;71(1):7–12.

    PubMed  CAS  Google Scholar 

  6. Schlumberger M, Pacini F, eds. Medullary thyroid carcinoma. In: Thyroid Tumors. Nucleon Paris. 1999: 267–307.

    Google Scholar 

  7. Kebebew E, Ituarte PHG, Siperstein AE, Duh Q-Y, Clark OH. Medullary thyroid carcinoma. Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139–48.

    PubMed  CAS  Google Scholar 

  8. Farndon J, Leight GS, Dilley WG, et al. Familial medullary thyroid carcinoma without assocaited endocrinopathies: a distinct clinical entity. Br J Surg. 1986;73:278–81.

    PubMed  CAS  Google Scholar 

  9. Nunziata V, Giannattasio R, di Giovanni G, D’Armiento MR, Mancini M. Hereditary localized pruritus in affected members of a kindred with multiple endocrine neoplasia type 2A (Sipples’ syndrome). Clin Endocrinol (Oxf). 1989;30:57–63.

    CAS  Google Scholar 

  10. Donovan DT, Levy ML, Furst EJ, et al. Familial cutaneous lichen amyloidosis in association with multiple endocrine neoplasia type 2A: a new variant. Henry Ford Hosp Med J. 1989;37(3–4):147–50.

    PubMed  CAS  Google Scholar 

  11. Ferrer JP, Halperin I, Conget JI, et al. Primary localized cutaneous amyloidosis and familial medullary thyroid carcinoma. Clin Endocrinol (Oxf). 1991;34(6): 435–9.

    CAS  Google Scholar 

  12. Verdy M, Weber AM, Roy CC, Morin CL, Cadotte M, Brochu P. Hirschsprung’s disease in a family with multiple endocrine neoplasia type 2A. J Pediatr Gastroenterol Nutr. 1982;1:603–7.

    PubMed  CAS  Google Scholar 

  13. Abdullah F, Udelsman R. Cutaneous lichen amyloidosis in a family with familial medullary thyroid cancer. Surgery. 2004;135(5):563–4.

    PubMed  Google Scholar 

  14. Williams E, Pollock DJ. Multiple mucosal neuromata with endocrine tumors: a syndrome allied to Von Recklinghausen’s disease. J Pathol Bacteriol. 1966;91: 71–80.

    PubMed  CAS  Google Scholar 

  15. Carney J, Go VL, Sizemore GW, Hayles AB. Alimentary-tract ganglioneuromatosis. A major component of the syndrome of multiple endocrine neoplasia, type 2b. N Engl J Med. 1976;295:1287–91.

    PubMed  CAS  Google Scholar 

  16. Carney JA, Sizemore GW, Hayles AB. Multiple endocrine neoplasia, type 2b. Pathobiol Annu. 1978;8:105–53.

    PubMed  CAS  Google Scholar 

  17. Copp DH. Calcitonin: discovery, development, and clinical application. Clin Invest Med. 1994;17(3):268–77.

    PubMed  CAS  Google Scholar 

  18. Copp DH, Cameron EC, Cheney BA, Davidson AG, Henze KG. Evidence for calcitonin — a new hormone from the parathyroid that lowers blood calcium. Endocrinology. 1962;70:638–49.

    PubMed  CAS  Google Scholar 

  19. Tashijan AH Jr, Howland BG, Melvin KE, Hill CS Jr. Immunoassay of human calcitonin. N Engl J Med. 1970; 283(17):890–5.

    PubMed  Google Scholar 

  20. Zaidi M I, AM, Moonga BS, Bevis PJ, Huang CL. Forty years of calcitonin–where are we now? A tribute to the work of Iain Macintyre, FRS. Bone, 2002. 30(5): p. 655–663.

    Google Scholar 

  21. Hazard J, Hawk WA, Crile G Jr. Medullary (solid) carcinoma of the thyroid, a clinicopathologic entity. J Clin Endocrinol Metab. 1959;19:152–61.

    PubMed  CAS  Google Scholar 

  22. Williams E. Histogenesis of medullary carcinoma of the thyroid. J Clin Pathol. 1966;19:114–8.

    PubMed  CAS  Google Scholar 

  23. Cunliffe W, Black MM, Hall R, et al. A calcitonin-secreting thyroid carcinoma. Lancet. 1968;2:63–8.

    Google Scholar 

  24. Tashjian AH Jr, Melvin KEW. Medullary carcinoma of the thyroid gland. Studies of thyrocalcitonin in plasma and tumor extracts. N Engl J Med. 1968;279:279–83.

    PubMed  Google Scholar 

  25. Melvin KE, Miller HH, Tashjian AH Jr. Early diagnosis of medullary carcinoma of the thyroid gland by means of calcitonin assay. N Engl J Med. 1971;285(20):1115–20.

    PubMed  CAS  Google Scholar 

  26. Hennessy JF, Gray TK, Cooper CW, Ontjes DA. Stimulation of thyrocalcitonin secretion by pentagastrin and calcium in 2 patients with medullary carcinoma of the thyroid. J Clin Endocrinol Metab. 1973;36(1):200–3.

    PubMed  CAS  Google Scholar 

  27. Sizemore GW, Go VL. Stimulation tests for diagnosis of medullary thyroid carcinoma. Mayo Clin Proc. 1975; 50(2):53–6.

    PubMed  CAS  Google Scholar 

  28. Melvin K, Tashjian AH Jr. The syndrome of excessive thyrocalcitonin produced by medullary carcinoma of the thyroid. Proc Natl Acad Sci U S A. 1968;59:1216–22.

    PubMed  CAS  Google Scholar 

  29. Sipple J. The association of pheochromocytoma with carcinoma of the thyroid. Am J Med. 1961;31:163–6.

    Google Scholar 

  30. Steiner A, Goodman AD, Powers SR. Study of kindred with pheochromocytoma, medullary thyroid carcinoma, hyperthyroidism and Cushing’s disease: multiple endocrine neoplasia type 2. Medicine. 1968;47: 371–409.

    PubMed  CAS  Google Scholar 

  31. Schimke RN, Hartmann WH. Familial amyloidproducing medullary thyroid carcinoma and pheochromocytoma. A distinct genetic entity. Ann Intern Med. 1965;63(6):1027–39.

    PubMed  CAS  Google Scholar 

  32. Block MA, Horn RC Jr, Miller JM, Barrett JL, Brush BE. Familial medullary carcinoma of the thyroid. Ann Surg. 1967;166(3):403–12.

    PubMed  CAS  Google Scholar 

  33. Markey WS, Ryan WG, Economou SG, Sizemore GW, Arnaud CD. Familial medullary carcinoma and parathyroid adenoma without pheochromocytoma. Report of two cases. Ann Intern Med. 1973;78(6): 898–901.

    PubMed  CAS  Google Scholar 

  34. Paloyan E, Scanu A, Straus FH, Pickleman JR, Paloyan D. Familial pheochromocytoma, medullary thyroid carcinoma, and parathyroid adenomas. JAMA. 1970; 214(8):1443–7.

    PubMed  CAS  Google Scholar 

  35. Catalona WJ, Engelman K, Ketcham AS, Hammond WG. Familial medullary thyroid carcinoma, pheochromocytoma, and parathyroid adenoma (Sipple’s syndrome). Study of a kindred. Cancer. 1971;28(5): 1245–54.

    PubMed  CAS  Google Scholar 

  36. Sato T, Seino M, Kitahara O, Ono I, Miura Y. Familial bilateral pheochromocytoma with medullary carcinoma of the thyroid. The second kindred of familial pheochromocytoma in Japan. Jpn Heart J. 1971; 12(4):405–13.

    PubMed  CAS  Google Scholar 

  37. Pearson KD, Wells SA, Keiser HR. Familial medullary carcinoma of the thyroid, adrenal pheochromocytoma and parathyroid hyperplasia. A syndrome of multiple endocrine neoplasia. Radiology. 1973;107(2):249–56.

    PubMed  CAS  Google Scholar 

  38. Nelkin BD, Nakamura Y, White RW, et al. Low incidence of loss of chromosome 10 in sporadic and hereditary human medullary thyroid carcinoma. Cancer Res. 1989;49(15):4114–9.

    PubMed  CAS  Google Scholar 

  39. Nelkin BD, Ball DW, Baylin SB. Molecular abnormalities in tumors associated with multiple endocrine neoplasia type 2. Endocrinol Metab Clin North Am. 1994;23(1):187–213.

    PubMed  CAS  Google Scholar 

  40. Donis-Keller H. The RET proto-oncogene and cancer. J Intern Med. 1995;238(4):319–25.

    PubMed  CAS  Google Scholar 

  41. Bachelot A, et al. Inheritable forms of medullary thyroid carcinoma. Biochimie. 2002;84(1):61–6.

    PubMed  CAS  Google Scholar 

  42. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med. 2003;349(16):1517–25.

    PubMed  CAS  Google Scholar 

  43. Boccia LM, Green JS, Joyce C, Eng C, Taylor SA, Mulligan LM. Mutation of RET codon 768 is associated with the FMTC phenotype. Clin Genet. 1997;51(2): 81–5.

    PubMed  CAS  Google Scholar 

  44. Yip L, Cote GJ, Shapiro SE, et al. Multiple endocrine neoplasia type 2: evaluation of the genotypephenotype relationship. Arch Surg. 2003;138(4):409–16; discussion 416.

    PubMed  CAS  Google Scholar 

  45. Puxeddu E, Fagin JA. Genetic markers in thyroid neoplasia. Endocrinol Metab Clin North Am. 2001;30(2): 493–513, x.

    PubMed  CAS  Google Scholar 

  46. Negri E, Ron E, Franceschi S, et al. Risk factors for medullary thyroid carcinoma: a pooled analysis. Cancer Causes Control. 2002;13(4):365–72.

    PubMed  Google Scholar 

  47. Nonidez J. The origin of the “parafollicular” cell: a second epithelial component of the thyroid gland of the dog. Am J Anat. 1932;49:475–505.

    Google Scholar 

  48. LiVolsi V. Medullary Carcinoma. Surgical Pathology of the Thyroid. Philadelphia: WB Saunders Co; 1990: 213–52.

    Google Scholar 

  49. Caillou B, Rougier P, Schlumberger M, Talbot M, Parmentier C. Value of immunohistochemistry in the study of medullary cancer of the thyroid. Implications of the results for the concept of the APUD system and of apudomas. Bull Cancer. 1984;71(2):140–4.

    PubMed  CAS  Google Scholar 

  50. Cote GJ, Gagel RF. Lessons learned from the management of a rare genetic cancer. N Engl J Med. 2003; 349(16):1566–8.

    PubMed  CAS  Google Scholar 

  51. Calmettes C. Calcitonin cancers: definition, history, various forms. Bull Cancer. 1984;71(2):114–21.

    PubMed  CAS  Google Scholar 

  52. Busnardo B, Girelli ME, Simoni N, Nacamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer. 1984;53:278–85.

    PubMed  CAS  Google Scholar 

  53. Mure A, Gicquel C, Abdelmoumene N, et al. Cushing’s syndrome in medullary thyroid carcinoma. J Endocrinol Invest. 1995;18(3):180–5.

    PubMed  CAS  Google Scholar 

  54. Smallridge RC, Bourne K, Pearson BW, Van Heerden JA, Carpenter PC, Young WF. Cushing’s syndrome due to medullary thyroid carcinoma: diagnosis by proopiomelanocortin messenger ribonucleic acid in situ hybridization. J Clin Endocrinol Metab. 2003;88(10): 4565–8.

    PubMed  CAS  Google Scholar 

  55. Blaustein A. Calcitonin secreting struma-carcinoid tumor of the ovary. Hum Pathol. 1979;10(2):222–8.

    PubMed  CAS  Google Scholar 

  56. Esik O, Nemeth G, Szepeshazi K. Calcitonin-secreting ovarian strumal carcinoid. Eur J Gynaecol Oncol. 1994; 15(3):211–6.

    PubMed  CAS  Google Scholar 

  57. Sugimoto F, Sekiya T, Saito M, et al. Calcitoninproducing pancreatic somatostatinoma: report of a case. Surg Today. 1998;28(12):1279–82.

    PubMed  CAS  Google Scholar 

  58. Rone JK, Lane AG, Grinkemeyer MD. Papillary thyroid carcinoma, parathyroid adenoma, and unexplained hypercalcitoninemia: an unusual presentation of multiple endocrine neoplasia type 2A? Thyroid. 1998;8(9): 781–5.

    PubMed  CAS  Google Scholar 

  59. Parker LN, Kollin J, Wu SY, Rypins EB, Juler GL. Carcinoma of the thyroid with a mixed medullary, papillary, follicular, and undifferentiated pattern. Arch Intern Med. 1985;145(8):1507–9.

    PubMed  CAS  Google Scholar 

  60. Gonzalez-Campora R, Lopez-Garrido J, Martin-Lacave I, Miralles-Sanchez EJ, Villar JL. Concurrence of a symptomatic encapsulated follicular carcinoma, an occult papillary carcinoma and a medullary carcinoma in the same patient. Histopathology. 1992;21(4):380–2.

    PubMed  CAS  Google Scholar 

  61. Meinhard K, Michailov I. [Simultaneous occurrence of medullary and papillary carcinoma in the same thyroid lobe]. Zentralbl Pathol. 1995;140(6):459–64.

    PubMed  CAS  Google Scholar 

  62. Tseleni-Balafouta S, Grigorakis SI, Alevizaki M, Karaiskos C, Davaris P, Koutras DA. Simultaneous occurrence of a medullary and a papillary thyroid carcinoma in the same patient. Gen Diagn Pathol. 1997;142(5–6):371–4.

    PubMed  CAS  Google Scholar 

  63. Mazziotti G, Rotondi M, Manganella G, et al. Medullary thyroid cancer, papillary thyroid microcarcinoma and Graves’ disease: an unusual clinical coexistence. J Endocrinol Invest. 2001;24(11):892–6.

    PubMed  CAS  Google Scholar 

  64. Kosem M, Kotan C, Algun E, Topal C. Simultaneous occurrence of papillary intrafollicular and microcarcinomas with bilateral medullary microcarcinoma of the thyroid in a patient with multiple endocrine neoplasia type 2A: report of a case. Surg Today. 2002;32(7):623–8.

    PubMed  Google Scholar 

  65. Fugazzola L, Cerutti N, Mannavola D, et al. Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer. Clin Endocrinol (Oxf). 2002; 56(1):53–63.

    CAS  Google Scholar 

  66. Papi G, Corrado S, Pomponi MG, Carapezzi C, Cesinaro A, LiVolsi VA. Concurrent lymph node metastases of medullary and papillary thyroid carcinoma in a case with RET oncogene germline mutation. Endocr Pathol. 2003;14(3):269–76.

    PubMed  CAS  Google Scholar 

  67. Abemayor E, Sidell N, Juillard G. Human medullary thyroid carcinoma. Initial characterization and in vitro differentiation of two new cell lines. Arch Otolaryngol Head Neck Surg. 1989;115(4):478–83.

    PubMed  CAS  Google Scholar 

  68. Felici A, Giorgio M, Krauzewicz N, et al. Medullary thyroid carcinomas in transgenic mice expressing a Polyoma carboxyl-terminal truncated middle-T and wild type small-T antigens. Oncogene. 1999;18(14): 2387–95.

    PubMed  CAS  Google Scholar 

  69. Cranston AN, Ponder BA. Modulation of medullary thyroid carcinoma penetrance suggests the presence of modifier genes in a RET transgenic mouse model. Cancer Res. 2003;63(16):4777–80.

    PubMed  CAS  Google Scholar 

  70. Ponder BA, Finer N, Coffey R, et al. Family screening in medullary thyroid carcinoma presenting without a family history. Q J Med. 1988;67(252):299–308.

    PubMed  CAS  Google Scholar 

  71. Verga U, Fugazzola L, Cambiaghi S, et al. Frequent association between MEN 2A and cutaneous lichen amyloidosis. Clin Endocrinol (Oxf). 2003;59(2):156–61.

    CAS  Google Scholar 

  72. Anderson RJ, Sizemore GW, Wahner HW, Carney JA. Thyroid scintigram in familial medullary carcinoma of the thyroid gland. Clin Nucl Med. 1978;3(4):147–51.

    PubMed  CAS  Google Scholar 

  73. Gagner M, Breton G, Pharand D, Pomp A. Is laparoscopic adrenalectomy indicated for pheochromocytomas? Surgery. 1996;120:1076–9.

    PubMed  CAS  Google Scholar 

  74. Lee J, Curley SA, Gagel RF, Evans DB, Hickey RC. Cortical-sparing adrenalectomy for patients with bilateral pheochromcytoma. Surgery. 1996;120:1064–70.

    PubMed  CAS  Google Scholar 

  75. Ali SZ, Teichberg S, Attie JN, Susin M. Medullary thyroid carcinoma metastatic to breast masquerading as infiltrating lobular carcinoma. Ann Clin Lab Sci. 1994;24(5):441–7.

    PubMed  CAS  Google Scholar 

  76. Jee MS, Chung YI, Lee MW, Choi JH, Moon KC, Koh JK. Cutaneous metastasis from medullary carcinoma of thyroid gland. Clin Exp Dermatol. 2003;28(6):670–1.

    PubMed  CAS  Google Scholar 

  77. Ordonez NG, Samaan NA. Medullary carcinoma of the thyroid metastatic to the skin: report of two cases. J Cutan Pathol. 1987;14(4):251–4.

    PubMed  CAS  Google Scholar 

  78. Esik O, Szavcsur P, Szakall S Jr, et al. Angiography effectively supports the diagnosis of hepatic metastases in medullary thyroid carcinoma. Cancer. 2001;91(11): 2084–95.

    PubMed  CAS  Google Scholar 

  79. Ponder BA. Setting up and running a familial cancer clinic. Br Med Bull. 1994;50(3):732–45.

    PubMed  CAS  Google Scholar 

  80. Freyer G, Ligneau B, Schlumberger M, et al. Quality of life in patients at risk of medullary thyroid carcinoma and followed by a comprehensive medical network: trends for future evaluations. Ann Oncol. 2001;12(10): 1461–5.

    PubMed  CAS  Google Scholar 

  81. Freyer G, Dazord A, Schlumberger M, et al. Psychosocial impact of genetic testing in familial medullarythyroid carcinoma: a multicentric pilot-evaluation. Ann Oncol. 1999;10(1):87–95.

    PubMed  CAS  Google Scholar 

  82. Graze K, et al. Natural history of familial medullary thyroid carcinoma: effect of a program for early diagnosis. N Engl J Med. 1978;299(18):980–5.

    PubMed  CAS  Google Scholar 

  83. Melvin KE, Tashjian AH Jr, Miller HH. Studies in familial (medullary) thyroid carcinoma. Recent Prog Horm Res. 1972;28:399–470.

    PubMed  CAS  Google Scholar 

  84. Raue F, Geiger S, Buhr H, Frank-Raue K, Ziegler R. The prognostic importance of calcitonin screening in familial medullary thyroid carcinoma. Dtsch Med Wochenschr. 1993;118(3):49–52.

    PubMed  CAS  Google Scholar 

  85. Wion-Barbot N, Schuffenecker I, Niccoli P, et al. Results of the calcitonin stimulation test in normal volunteers compared with genetically unaffected members of MEN 2A and familial medullary thyroid carcinoma families. Ann Endocrinol (Paris). 1997;58(4): 302–8.

    CAS  Google Scholar 

  86. Starling JR, Harris C, Granner DK. Diagnosis of occult familial medullary carcinoma of the thyroid using pentagastrin. Arch Surg. 1978;113(3):241–3.

    PubMed  CAS  Google Scholar 

  87. Dymling JF, Ljungberg O, Hillyard CJ, Greenberg PB, Evans IM, MacIntyre I. Whisky: a new provacative test for calcitonin secretion. Acta Endocrinol (Copenh). 1976;82(3):500–9.

    CAS  Google Scholar 

  88. Milhaud G, Ribeiro FM, Calmettes C, Taboulet J, Coutris G, Moukhtar MS. [Tests of stimulation of calcitonin secretion. Value in medullary cancer of the thyroid]. Nouv Presse Med. 1975;4(24):1793–5.

    PubMed  CAS  Google Scholar 

  89. Elisei R, Bottici V, Luchett F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab. 2004;89(1):163–8.

    PubMed  CAS  Google Scholar 

  90. Iacobone M, Niccoli-Sire P, Sebag F, De Micco C, Henry JF. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels. World J Surg. 2002;26(8):886–90.

    PubMed  Google Scholar 

  91. Melvin KE, Tashjian AH Jr, Cassidy CE, Givens JR. Cushing’s syndrome caused by ACTH-and calcitonin-secreting medullary carcinoma of the thyroid. Metabolism. 1970;19(10):831–8.

    PubMed  CAS  Google Scholar 

  92. Niccoli P, Conte-Devolx B, Lejeune PJ, et al. [Hypercalcitoninemia in conditions other than medullary cancers of the thyroid]. Ann Endocrinol (Paris). 1996; 57(1):15–21.

    CAS  Google Scholar 

  93. Vierhapper H, Nowotny P, Bieglmayer C, Gessl A. Prevalence of hypergastrinemia in patients with hyper-and hypothyroidism: impact for calcitonin? Horm Res. 2002;57(3–4):85–9.

    PubMed  CAS  Google Scholar 

  94. Brandi M, Gagel RF, Angeli A, et al. Consensus: Guidelines for diagnosis and therapy of MEN Type 1 and 2. J Clin Endocrinol Metab. 2001;86:5658–71.

    PubMed  CAS  Google Scholar 

  95. NCCN, Practice Guidelines in Oncology-v.1. 2003. Thyroid Cancer: Medullary Cancer. CD available from National Comprehensive Cancer Network. 2004.

    Google Scholar 

  96. Niccoli-Sire P, Murat A, Rohmer V, et al. When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations? Surgery. 2003;134(6):1029–36; discussion 1036–7.

    PubMed  Google Scholar 

  97. Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery. 2003;134(6): 890–9; discussion 899–901.

    PubMed  Google Scholar 

  98. Franc S, Niccoli-Sire P, Cohen R, et al. Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2001;55(3):403–9.

    CAS  Google Scholar 

  99. Pender S, Little DM, Burke P, Broe P. Treatment of medullary carcinoma of the thyroid by laryngopharyngo-oesophagectomy — a case report. Ir J Med Sci. 1992;161(7):450–1.

    PubMed  CAS  Google Scholar 

  100. Hellman D, Kartchner M, Van Antwerp JD, Salmon SE, Patton DD, O’Mara R. Radioiodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab. 1979;48:451–5.

    PubMed  CAS  Google Scholar 

  101. Saad MF, Guido JJ, Samaan NA. Radioactive iodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab. 1983;57(1):124–8.

    PubMed  CAS  Google Scholar 

  102. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Tagliaferri P. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer. 2001;91(9):1797–808.

    PubMed  CAS  Google Scholar 

  103. Bellantone R, Boscherini, M, Lombardi CP, Alesina PF. Medullary thyroid carcinoma: surgical management of primary tumor and locoregional recurrence. Rays. 2000;25(2):267–71.

    PubMed  CAS  Google Scholar 

  104. Pollinger B, Duhmke E. External radiotherapy of thyroid cancer. Onkologie. 2001;24(2):134–8.

    PubMed  CAS  Google Scholar 

  105. Simpson WJ, Palmer JA, Rosen IB, Mustard RA. Management of medullary carcinoma of the thyroid. Am J Surg. 1982;144(4):420–2.

    PubMed  CAS  Google Scholar 

  106. Samaan NA, Schultz PN, Hickey RC. Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab. 1988;67(4):801–5.

    PubMed  CAS  Google Scholar 

  107. Tubiana M, Haddad E, Schlumberger M, Hill C, Rougier P, Sarrazin D. External radiotherapy in thyroid cancers. Cancer. 1985;55(9 Suppl):2062–71.

    PubMed  CAS  Google Scholar 

  108. Sarrazin D, Fontaine F, Rougier P, et al. [Role of radiotherapy in the treatment of medullary cancer of the thyroid]. Bull Cancer. 1984;71(3):200–8.

    PubMed  CAS  Google Scholar 

  109. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid. 1996; 6(4):305–10.

    PubMed  CAS  Google Scholar 

  110. Behr TM, Gratz S, Markus PM, et al. Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes (“chimney sign”) in occult metastatic medullary thyroid cancer: a typical site of tumour manifestation? Eur J Nucl Med. 1997;24(2):184–91.

    PubMed  CAS  Google Scholar 

  111. Harmer C, Bidmead M, Shepherd S, Sharpe A, Vini L. Radiotherapy planning techniques for thyroid cancer. Br J Radiol. 1998;71(850):1069–75.

    PubMed  CAS  Google Scholar 

  112. Monsieurs M, Brans B, Bacher K, Dierckx R, Thierens H. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans. Eur J Nucl Med Mol Imaging. 2002;29(12):1581–7.

    PubMed  CAS  Google Scholar 

  113. Bombardieri E, Maccauro M, Castellani MR, et al. [Radioisotopic imaging of neuroendocrine tumours. Which radiopharmaceutical and which diagnostic procedure?]. Minerva Endocrinol. 2001;26(4):197–213.

    PubMed  CAS  Google Scholar 

  114. Castellani MR, Alessi A, Savelli G, Bombardieri E. The role of radionuclide therapy in medullary thyroid cancer. Tumori. 2003;89(5):560–2.

    PubMed  CAS  Google Scholar 

  115. Hoefnagel C, Delprat CC, Zanin D, et al. New radionuclide tracers for the diagnosis and therapy of medullary cancer. Clin Nucl Med. 1988;13:159.

    PubMed  CAS  Google Scholar 

  116. Hoefnagel CA, Delprat CC, Valdes Olmos RA. Role of [131I]metaiodobenzylguanidine therapy in medullary thyroid carcinoma. J Nucl Biol Med. 1991; 35(4):334–6.

    PubMed  CAS  Google Scholar 

  117. Wiseman GA, Kvols LK. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin Nucl Med. 1995;25(3):272–8.

    PubMed  CAS  Google Scholar 

  118. Shapiro B. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks. Q J Nucl Med. 1995;39(4 Suppl 1):150–5.

    PubMed  CAS  Google Scholar 

  119. Juweid ME, Hajjar G, Stein R, et al. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. J Nucl Med. 2000;41(1):93–103.

    PubMed  CAS  Google Scholar 

  120. Behr TM, Sharkey RM, Juweid ME, et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med. 1997;38(6):858–70.

    PubMed  CAS  Google Scholar 

  121. Forssell-Aronsson EB, Nilsson O, Bejegard SA et al. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med. 2000;41(4):636–42.

    PubMed  CAS  Google Scholar 

  122. Yang KP, Liang YF, Samaan NA. Intrinsic drug resistance in a human medullary thyroid carcinoma cell line: association with overexpression of mdrl gene and low proliferation fraction. Anticancer Res. 1991;11(3): 1065–8.

    PubMed  CAS  Google Scholar 

  123. Porter AT, Ostrowski MJ. Medullary carcinoma of the thyroid treated by low-dose Adriamycin. Br J Clin Pract. 1990;44(11):517–8.

    PubMed  CAS  Google Scholar 

  124. Scherubl H, Raue F, Ziegler R. Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol. 1990;116(1):21–3.

    PubMed  CAS  Google Scholar 

  125. Ravry MJ. Response of medullary thyroid carcinomas and carcinoid tumors to adriamycin. Cancer Treat Rep. 1977;61(1):106–7.

    PubMed  CAS  Google Scholar 

  126. Frame J, Kelsen D, Kemeny N, et al. A phase II trial of streptozotocin and adriamycin in advanced APUD tumors. Am J Clin Oncol. 1988;11(4):490–5.

    PubMed  CAS  Google Scholar 

  127. Petursson SR. Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer. 1988; 62(9):1899–903.

    PubMed  CAS  Google Scholar 

  128. Orlandi F, Caraci P, Berruti A, et al. Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol. 1994;5(8):763–5.

    PubMed  CAS  Google Scholar 

  129. Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FUstreptozocin and 5 FU-dacarbazine. The Groupe d’Etude des Tumeurs a Calcitonine (GETC). Br J Cancer. 1995;71(2):363–5.

    PubMed  CAS  Google Scholar 

  130. Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d’Etude des Tumeurs a Calcitonine (GETC). Br J Cancer. 2000;83(6):715–8.

    PubMed  CAS  Google Scholar 

  131. Orlandi F, Caraci P, Mussa A, Saggiorato E, Pancani G, Angeli A. Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer. 2001;8(2):135–47.

    PubMed  CAS  Google Scholar 

  132. Mahler C, Verhelst J, de Longueville M, Harris A. Longterm treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol (Oxf). 1990;33(2):261–9.

    CAS  Google Scholar 

  133. Libroia A, Verga U, Di Sacco G, Piolini M, Muratori F. Use of somatostatin analog SMS 201–995 in medullary thyroid carcinoma. Henry Ford Hosp Med J. 1989; 37(3–4):151–3.

    PubMed  CAS  Google Scholar 

  134. Ahlman H, Tisell LE. The use of a long-acting somatostatin analogue in the treatment of advanced endocrine malignancies with gastrointestinal symptoms. Scand J Gastroenterol. 1987;22(8):938–42.

    PubMed  CAS  Google Scholar 

  135. Zatelli MC, degli Uberti EC. Somatostatin receptors: from basic science to clinical approach — thyroid. Dig Liver Dis. 2004;36 Suppl 1:S86–92.

    PubMed  CAS  Google Scholar 

  136. Lanzi C, Cassinelli G, Cuccuru G, Zanchi C, Laccabue D, Zunino F. RET/PTC oncoproteins: molecular targets of new drugs. Tumori. 2003;89(5):520–2.

    PubMed  CAS  Google Scholar 

  137. Skinner MA, Safford SD, Freemerman AJ. RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571. Anticancer Res. 2003;23(5A): 3601–6.

    PubMed  CAS  Google Scholar 

  138. Fawell WNT, G. Nutmeg for diarrhea of medullary carcinoma of thyroid. N Engl J Med. 1973;289(2): 108–9.

    PubMed  CAS  Google Scholar 

  139. Bernier JJR, JC, Cattan D, Prost A. Diarrhoea associated with medullary carcinoma of the thyroid. Gut. 1969; 10(12):980–5.

    PubMed  CAS  Google Scholar 

  140. Saad MF, Fritsche HA Jr, Samaan NA. Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid. J Clin Endocrinol Metab. 1984;58(5):889–94.

    PubMed  CAS  Google Scholar 

  141. Stepanas AV, Samaan NA, Hill CS Jr, Hickey RC. Medullary thyroid carcinoma: importance of serial serum calcitonin measurement. Cancer. 1979;43(3): 825–37.

    PubMed  CAS  Google Scholar 

  142. Rufini V, et al. Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma. Rays. 2000;25(2):273–82.

    PubMed  CAS  Google Scholar 

  143. Keeling CA, Basso LV. Iodine-131 MIBG uptake in metastatic medullary carcinoma of the thyroid. A patient treated with somatostatin. Clin Nucl Med. 1988; 13(4):260–3.

    PubMed  CAS  Google Scholar 

  144. Simon GH, Nitzsche EU, Laubenberger JJ, Einert A, Moser E. PET imaging of recurrent medullary thyroid cancer. Nuklearmedizin. 1996;35(3):102–4.

    PubMed  CAS  Google Scholar 

  145. Zhang J, et al. [Detection of remnants after removal of medullary thyroid carcinoma]. Zhonghua Wai Ke Za Zhi. 2000;38(1):19–21.

    PubMed  CAS  Google Scholar 

  146. Adams BK, Fataar A, Byrne MJ, Levitt NS, Matley PJ. Pentavalent technetium-99m (V)-DMSA uptake in a pheochromocytoma in a patient with Sipple’s syndrome. J Nucl Med. 1990;31(1):106–8.

    PubMed  CAS  Google Scholar 

  147. Shikare S, Bashir K, Menon PS, Bapat RD, Tilve GH. Detection of medullary carcinoma of thyroid, with liver metastasis, using 99mTc DMSA(V) scintigraphy. J Postgrad Med. 1995;41(1):12–3.

    PubMed  CAS  Google Scholar 

  148. Bisunadan MM, et al. Synthesis and characterization of [186Re]rhenium(V)dimercaptosuccinic acid: a possible tumour radiotherapy agent. Int J Rad Appl Instrum[A]. 1991;42(2):167–71.

    CAS  Google Scholar 

  149. Blower PJ, et al. Pentavalent rhenium-188 dimercaptosuccinic acid for targeted radiotherapy: synthesis and preliminary animal and human studies. Eur J Nucl Med. 1998;25(6):613–21.

    PubMed  CAS  Google Scholar 

  150. Ugur O, Kostaglu L, Guler N, et al. Comparison of 99mTc (V)-DMSA, 201Tl, and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. Eur J Nucl Med. 1996;23:1367–81.

    PubMed  CAS  Google Scholar 

  151. Adalet I, Demirkale P, Unal S, Ouz H, Alagol F, Cantez S. Disappointing results with Tc-99m tetrofosmin for detecting medullary thyroid carcinoma metastases comparison with Tc-99m VDMSA and TI-201. Clin Nucl Med. 1999;24(9):678–83.

    PubMed  CAS  Google Scholar 

  152. Roelants V, Michel L, Lonneux M, Lacrosse M, Delgrange E, Donckier JE. Usefulness of [99mTC]MIBI and [18F]fluorodeoxyglucose for imaging recurrent medullary thyroid cancer and hyperparathyroidism in MEN 2a syndrome. Acta Clin Belg. 2001;56(6):373–7.

    PubMed  CAS  Google Scholar 

  153. Chen YK, Liu FY, Yen RF, Kao CH. Compare FDG-PET and Tc-99m tetrofosmin SPECT to detect metastatic thyroid carcinoma. Acad Radiol. 2003;10(8):835–9.

    PubMed  Google Scholar 

  154. Behr TM, Gratz S, Markus PM, et al. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Cancer. 1997;80(12 Suppl):2436–57.

    PubMed  CAS  Google Scholar 

  155. Bockisch A, Brandt-Mainz K, Gorges R, Muller S, Stattaus J, Antoch G. Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner. Acta Med Austriaca. 2003;30(1):22–5.

    PubMed  CAS  Google Scholar 

  156. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998;25(1):79–83.

    PubMed  CAS  Google Scholar 

  157. Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med. 2000;27(5):490–6.

    PubMed  CAS  Google Scholar 

  158. Szakall S Jr, Esik O, Bajzik G, et al. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med. 2002;43(1):66–71.

    PubMed  Google Scholar 

  159. Shulkins BL, T N, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: Imaging with 2-[Fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology. 1999; 212:35–41.

    Google Scholar 

  160. Gasparoni P, Rubello D, Ferlin G. Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma. J Endocrinol Invest. 1997;20(9):527–30.

    PubMed  CAS  Google Scholar 

  161. Cook G, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET with 18-fluoro-2-deoxyglucose and carbon-11 methionine., Normal variants, artefacts and interpretative pitfalls in PET with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med. 1999;26:1363–78.

    PubMed  CAS  Google Scholar 

  162. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19(1):61–77; quiz 150-1.

    PubMed  CAS  Google Scholar 

  163. Barrington S, Maisey MN. Skeletal muscle uptake of fluorine-18 FDG: effect of oral diazepam. J Nucl Med. 1996;37:1127–29.

    PubMed  CAS  Google Scholar 

  164. Igerc I, Kumnig G, Heinisch M, et al. Vocal cord muscle activity as a drawback to FDG-PET in the followup of differentiated thyroid cancer. Thyroid. 2002;12(1):87–9.

    PubMed  CAS  Google Scholar 

  165. Zhu Z, et al. Elevated F-18 FDG uptake in laryngeal muscles mimicking thyroid cancer metastases. Clin Nucl Med. 2001;26(8):689–91.

    PubMed  CAS  Google Scholar 

  166. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Whatley M, Goldstein DS. Diagnostic localization of pheochromocytoma: the coming of age of positron emission tomography. Ann NY Acad Sci. 2002;970: 170–6.

    PubMed  CAS  Google Scholar 

  167. Gourgiotis L, Sarlis NJ, Reynolds JC, VanWaes C, Merino MJ, Pacak K. Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-fluorodopamine positron emission tomography. J Clin Endocrinol Metab. 2003;88(2):637–41.

    PubMed  CAS  Google Scholar 

  168. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28(1):64–71.

    PubMed  CAS  Google Scholar 

  169. Hoegerle S, Nitzsche E, Altehoefer C, et al. Pheochromocytomas: detection with 18F DOPA whole body PET — initial results. Radiology. 2002;222(2):507–12.

    PubMed  Google Scholar 

  170. Ilias I, Yu J, Carrasquillo JA, et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab. 2003;88(9):4083–7.

    PubMed  CAS  Google Scholar 

  171. Gimm O, Sutter T, Dralle H. Diagnosis and therapy of sporadic and familial thyroid carcinoma. J Cancer Res Clin Oncol. 2001;127:156–65.

    PubMed  CAS  Google Scholar 

  172. Murat A. [Detection of residual lesions and metastases of medullary thyroid cancer]. Ann Endocrinol (Paris). 1996;57(1):27–32.

    CAS  Google Scholar 

  173. Medina-Franco H, et al. Persistent hypercalcitoninemia in patients with medullary thyroid cancer: a therapeutic approach based on selective venous sampling for calcitonin. Rev Invest Clin. 2001;53(3):212–7.

    PubMed  CAS  Google Scholar 

  174. Abdelmoumene N, et al. Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma. Br J Cancer. 1994;69(6):1141–4.

    PubMed  CAS  Google Scholar 

  175. Frank-Raue K, et al. Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization. Thyroid. 1992;2(2):113–7.

    PubMed  CAS  Google Scholar 

  176. Ben Mrad MD, et al. Value of venous catheterization and calcitonin studies in the treatment and management of clinically inapparent medullary thyroid carcinoma. Cancer. 1989;63(1):133–8.

    PubMed  Google Scholar 

  177. Kakudo K, Carney JA, Sizemore GW. Medullary carcinoma of thyroid. Biologic behavior of the sporadic and familial neoplasm. Cancer. 1985;55(12):2818–21.

    PubMed  CAS  Google Scholar 

  178. Beressi N, Campos JM, Beressi JP, et al. Sporadic medullary microcarcinoma of the thyroid: a retrospective analysis of eighty cases. Thyroid. 1998;8(11): 1039–44.

    PubMed  CAS  Google Scholar 

  179. Zangeneh F, Gharib H, Goellner JR, Kao PC. Potential absence of prognostic implications of severe preoperative hypercalcitoninemia in medullary thyroid carcinoma. Endocr Pract. 2003;9(4):284–9.

    PubMed  Google Scholar 

  180. Esik O, Tusnady G, Tron L, et al. Markov model-based estimation of individual survival probability for medullary thyroid cancer patients. Pathol Oncol Res. 2002;8(2):93–104.

    PubMed  Google Scholar 

  181. Gharib H, McConahey WM, Tiegs RD, et al. Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clin Proc. 1992;67(10):934–40.

    PubMed  CAS  Google Scholar 

  182. Raue F. German medullary thyroid carcinoma/multiple endocrine neoplasia registry. German MTC/MEN Study Group. Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia Type 2. Langenbecks Arch Surg. 1998;383(5):334–6.

    PubMed  CAS  Google Scholar 

  183. Randolph G, Maniar D. Medullary carcinoma of the thyroid. Cancer Control. 2000;7:253–61.

    PubMed  CAS  Google Scholar 

  184. Hyer S, Vini L, A’Hern R, Harmer C. Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol. 2000;26:686–90.

    PubMed  CAS  Google Scholar 

  185. Bergholm U, et al. Long-term survival in sporadic and familial medullary thyroid carcinoma with special reference to clinical characteristics as prognostic factors. The Swedish MTC Study Group. Acta Chir Scand. 1990;156(1):37–46.

    PubMed  CAS  Google Scholar 

  186. Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore). 1984;63(6):319–42.

    CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag London Limited

About this chapter

Cite this chapter

(2006). Medullary Cancer. In: Management of Thyroid Cancer and Related Nodular Disease. Springer, London . https://doi.org/10.1007/1-84628-006-0_10

Download citation

  • DOI: https://doi.org/10.1007/1-84628-006-0_10

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-965-4

  • Online ISBN: 978-1-84628-006-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation